PD-1 Does Not Mark Tumor-infiltrating CD8+ T Cell Dysfunction in Human Gastric Cancer
Overview
Oncology
Pharmacology
Authors
Affiliations
Background: Overexpression of programmed cell death protein 1 (PD-1) is linked to CD8+ T cell dysfunction and contributes to tumor immune escape. However, the prevalence and functional regulations of PD-1 expression on CD8+ T cells in human gastric cancer (GC) remain largely unknown.
Methods: Flow cytometry was performed to analyze the level, phenotype, functional and clinical relevance of PD-1+CD8+ T cells in GC patients. Peripheral blood CD8+ T cells were purified and subsequently exposed to culture supernatants from digested primary GC tumor tissues (TSN) in vitro for PD-1 expression and functional assays. Tumor responses to adoptively transferred TSN-stimulated CD8+ T cells or to the TSN-stimulated CD8+ T cell transfer combined with an anti-PD-1 antibody injection were measured in an in vivo xenograft mouse model.
Results: GC patients' tumors showed a significantly increased PD-1+CD8+ T cell infiltration. However, these GC-infiltrating PD-1+CD8+ T cells showed equivalent function to their PD-1-CD8+ counterparts and they did not predict tumor progression. High level of transforming growth factor-β1 (TGF-β1) in tumors was positively correlated with PD-1+CD8+ T cell infiltration, and in vitro GC-derived TGF-β1 induced PD-1 expression on CD8+ T cells via Smad3 signaling, whereas Smad2 signaling was involved in GC-derived TGF-β1-mediated CD8+ T cell dysfunction. Furthermore, GC-derived TGF-β1-mediated CD8+ T cell dysfunction contributed to tumor growth in vivo that could not be attenuated by PD-1 blockade.
Conclusions: Our data highlight that GC-derived TGF-β1 promotes PD-1 independent CD8+ T cell dysfunction. Therefore, restoring CD8+ T cell function by a combinational PD-1 and TGF-β1 blockade might benefit future GC immunotherapy.
Clinical significance of the tumor microenvironment on immune tolerance in gastric cancer.
He X, Guan X, Li Y Front Immunol. 2025; 16:1532605.
PMID: 40028336 PMC: 11868122. DOI: 10.3389/fimmu.2025.1532605.
Yen Y, Zhang Z, Chen A, Qiu Y, Liu Q, Wang Q J Nanobiotechnology. 2025; 23(1):124.
PMID: 39972327 PMC: 11841268. DOI: 10.1186/s12951-025-03129-z.
Wan Z, Cui M, Yang J, Liao D, Chen J, Li F Front Oncol. 2025; 14:1531219.
PMID: 39876901 PMC: 11772205. DOI: 10.3389/fonc.2024.1531219.
Melique S, Vadel A, Rouquie N, Yang C, Bories C, Cotineau C Proc Natl Acad Sci U S A. 2024; 121(20):e2318773121.
PMID: 38713628 PMC: 11098085. DOI: 10.1073/pnas.2318773121.
Shin K, Kim J, Park S, Kim H, Lee M, Kim O Cancers (Basel). 2023; 15(15).
PMID: 37568771 PMC: 10417033. DOI: 10.3390/cancers15153955.